Latest: FDA Approves New Biosimilar for Oncology Treatment

Amycretin significantly improves weight loss in patients with overweight or obese body weight

0 Mins

1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2. Amycretin resulted in significant weight loss across most doses compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Amycretin is a novel therapy that activates GLP-1 and amylin receptors, two hormones involved in regulating appetite and metabolism. Until […]

The post Amycretin significantly improves weight loss in patients with overweight or obese body weight first appeared on 2 Minute Medicine.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago